QIAGEN N.V. · ISIN: NL0015002CX3 · EQS - adhoc news

QIAGEN to propose initiation of annual cash dividend for shareholder approval at Annual General Meeting

Ad hoc Announcement according to Art. 17 Market Abuse Regulation QIAGEN to propose initiation of annual cash dividend for shareholder approval at Annual General Meeting Venlo, the Netherlands, May 7, 2025 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces that its Supervisory Board will propose the initiation of an annual cash dividend under an amended dividend policy to QIAGEN’s shareholders at the next Annual General Meeting scheduled for June 26, 2025. This milestone refl...

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News QIAGEN N.V.

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
07 May 2025 02:35PM
QIAGEN to propose initiation of annual cash dividend for shareholder approval at Annual General Meeting
Ad hoc Announcement according to Art. 17 Market Abuse Regulation QIAGEN to propose initiation of annual cash dividend for shareholder approval at Annual General Meeting Venlo, the Netherlands, May 7, 2025 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces that its Supervisory Board will propose the initiation of an annual cash d...
QIAGEN N.V.
06 April 2025 06:20PM
QIAGEN announces strong preliminary Q1 2025 results and updates full-year 2025 adjusted earnings per share outlook
Ad hoc Announcement according to Art. 17 Market Abuse Regulation QIAGEN announces strong preliminary Q1 2025 results and updates full-year 2025 adjusted earnings per share outlook Venlo, the Netherlands, April 6, 2025 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces preliminary Q1 2025 results that exceed the outlook for both n...
QIAGEN N.V.
More QIAGEN N.V. related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN